Prof. Dr. med. Dr. h.c. Christoph Lange

Curriculum vitae Prof. Dr. med. Dr. h.c. Christoph Lange, FIDSA, FESCMID, FERS

Stand: 24.09.2024

Funktion

• Medizinischer Direktor am Forschungszentrum Borstel
• Professor (W3) für Respiratory Medicine & International Health an der Universität zu Lübeck (beamtet)
• Leiter der Forschergruppe Klinische Infektiologie am Forschungszentrum Borstel.
• Leiter der klinischen Tuberkuloseeinheit im Deutschen Zentrum für Infektionsforschung
• Leitung der Medizinischen Infrastrukturen (Pathologie, MVZ, Studienzentrum und Biobank) am Forschungszentrum Borstel

Forschungs- /Tätigkeitsprofil

• Forschungsschwerpunkt auf dem Gebiet der Tuberkulose (Antibiotika-Resistenz, Epidemiologie, Prävention, Diagnostik und Therapie)
• Stichworte: Biomarker, personalisierte Medizin, Kohortenstudien, M/XDR-TB, TBNET Osteuropa, südliches Afrika

Berufliche Meilensteine

• 2022: Facharzt für Innere Medizin und Infektiologie
• 2018-: Medizinischer Direktor des Forschungszentrums Borstel
• 2017-2021: Chefarzt der Medizinische Klinik des Forschungszentrums Borstel
• 2014-: Professor (W3) für International Health/Infectious Diseases
  (umgewidmet 2018 in: Respiratory Medicine & International Health) an der Universität zu Lübeck
• 2009-2017: Chefarzt der Medizinische Klinik des Forschungszentrums Borstel Professor (W3) für International Health/Infectious Diseases
  (umgewidmet 2018 in: Respiratory Medicine & International Health) an der Universität zu Lübeck Leitender Oberarzt, Medizinische Klinik des Forschungszentrums Borstel
• 2004: Habilitation in Innerer Medizin
• 2001-2009: Schwerpunktbezeichnung in Pneumologie (2003) und Zusatzbezeichnungen in Infektiologie (2006), Allergologie (2008), Intensivmedizin (2008) und Schlafmedizin (2009); Ausbildung an der Medizinische Klinik des Forschungszentrums Borstel
• 2001: Facharzt Innere Medizin
• 1999-2001: Fellowship in Klinischer Infektiologie (CWRU, Cleveland, Ohio, USA)
• 1995-1999: Ausbildung in Innerer Medizin (UCT Kapstadt, KKH Preetz und KKH Rendsburg)
• 1995: Promotion (Dr. med.)
• 1994: 3. Medizinisches Staatsexamen (Universität Witten Herdecke)
• 1988: Biologie Diplom (Christian-Albrechts-Universität zu Kiel)

Ämter und Funktionen außerhalb des FZB

• 2023-: Direktor (Generalsekretär) der Int. Union against Tuberculosis & Lung Diseases
• 2021-: Guest Professor, Baylor College of Medicine, Texas Children´s Hospital, Houston, TX, USA
• 2018-: Mitglied im Lenkungsausschuss der Exzellenzclusters „Precision Medicine“ der Universität zu Kiel
• 2018-2021: Foreign Adjunct Professor, Arctic Tuberculosis Center, University Umeå, Sweden
• 2015-: Mitglied im Lenkungsausschuss der Akademie des Deutschen Zentrums für Infektionsforschung (DZIF)
• 2014-2019: Foreign Adjunct Professor, Karolinska Institut, Stockholm, Schweden
• 2013-2017: Adjunct Professor of Medicine, University of Namibia, Windhoek, Namibia
• 2013-: Vorstand der Schleswig-Holsteinischen Gesellschaft zur Verhütung und Bekämpfung der Tuberkulose und der Lungenkrankheiten e.V., stellv. Vorsitzender
• 2012-: Adjunct Professor of Medicine, USMF, Chisinau, Republik Moldau
• 2011-2014: Sprecher: Respiratory Infections Assembly, European Respiratory Society
• 2006-: Mitglied des Steering Committees der Tuberculosis Network European Trialsgroup (TBNET), Sprecher von 2006-2012
• 2005-: Mitglied der Ethikkommission der Ärztekammer Schleswig-Holstein, stellv. Vorsitzender seit 2013

Aktuelle Projekte

• 2021-2027: EU-IMI UNITE4TB, Klinischer Ko-Leiter
• 2019-2025: Excellence Cluster Personalized Medicine, CD3; WP Ko-Leiter
• 2019-2025: EDCTP: ClicTB; WP Leiter
• 2021-2024: EDCTP: stool4TB; WP Leiter
• 2016-2025: DZIF ClinTB; Leiter
• 2016-2025: DZIF TTU TB: Personalized Medicine; Ko-Koordinator
• 2016-2025: DZIF Eastern European Study Site; Bucharest, Rumänien; Ko-Koordinator

Preise/Auszeichnungen

• 2023: Hinduja Hospital Oration Award, Mumbai, Indien
• 2018: Memento Forschungspreis für vernachlässigte Erkrankungen (Ärzte ohne Grenzen, Brot für die Welt, DAHW und Buko Pharmainitiative)
• 2017: Spinoza Chair of Medicine, Universität Amsterdam, Niederlande
• 2017: Fellow of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
• 2014: Fellow of the European Respiratory Society (ERS)
• 2015: Wissenschaftspreis des Stifterverbandes für die Deutsche Wissenschaft
• 2013: Doctor honoris causa, USMF, Chisinau, Rep. Moldau
• 2006: Fellow of the Infectious Diseases Society of America (IDSA)
• 2003: Hector Forschungspreis zur Pathogenese der HIV-Infektion

Indikatoren

• h-index: 87; i10-index: 253; Zitationen: 31329, IF Σ = 5316 (IF von 2023)

Ausgewählte Publikationen 2022-2024

2024

• Brehm TT, et al. (Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review. Clin Microbiol Infect. 2024 Apr 23: S1198-743X(24)00206-4. doi: 10.1016/j.cmi.2024.04.011.
• Carratalà Castro L, et al. Use of stool-based molecular tests for pediatric tuberculosis diagnosis: a systematic review and meta-analysis. Lancet Microbe. 2024 (in press)
• Cirillo DM et al. Handing over the baton: A successful UN High-Level Meeting on AMR must build on the 2023 UN High-Level Meeting on TB. Lancet Glob Health. 2024 Aug;12(8):e1225-e1226. doi: 10.1016/S2214-109X(24)00229-8.
• Dheda K, et al. Multidrug-resistant tuberculosis. Nat Rev Dis Primers. 2024 Mar 24;10(1):22. doi: 10.1038/s41572-024-00504-2.
• Dheda K et al. Towards shorter, safer, flexible and more effective treatment regimens for drug-resistant tuberculosis. Lancet Respir Med 2024 (in press)
• Diacon AH, et al.. Fourteen-day treatment responses in participants with rifampicin-susceptible pulmonary tuberculosis receiving the leucyl-tRNA synthetase inhibitor GSK3036656: a phase 2a open-label, randomized trial. Nat Med 2024 https://doi.org/10.1038/s41591-024-02829-7
• Gillespie SH, et al. Developing biomarkers assays to accelerate tuberculosis drug development: defining target product profiles. Lancet Microbe 2024, Published Online, https://doi.org/10.1016/S2666-5247(24)00085-5
• Günther G, et al.  Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe. Clin Microbiol Infect. 2024 Mar 13:S1198-743X(24)00121-6. doi: 10.1016/j.cmi.2024.03.009
• Hoelscher M, et al. Candidate anti-tuberculosis medicines and regimens under clinical evaluation. Clin Microbiol Infect. 2024 Jun 21:S1198-743X(24)00296-9. doi: 10.1016/j.cmi.2024.06.016.
• Kay A, et al. Performance of a quantitative stool polymerase chain reaction assay for the diagnosis of tuberculosis: a multinational diagnostic accuracy study. Lancet Microbe 2024 Mar 7: S2666-5247(23)00391-9. doi: 10.1016/S2666-5247(23)00391-9.
• Lienhardt C, et al. Target regimen profiles: shaping the future of tuberculosis treatment. Bull World Health Organ. 2024 Aug 1;102(8):600-607. doi: 10.2471/BLT.24.291881.
• Martinez L, et al. Effectiveness of preventive treatment among persons with differing age and Mycobacterium tuberculosis infection status: A systematic review and individual-participant meta-analysis of contact tracing studies Lancet Respir Med 2024 Published Online, https://doi.org/10.1016/S2213-2600(24)00083-3
• Nyang'wa BT, et al.  Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med. 2024 Feb;12(2):117-128. doi: 10.1016/S2213-2600(23)00389-2
• Shaw ES, et al. Bedaquiline: what might the future hold? Lancet Microbe. 2024 Jul 26:100909. doi: 10.1016/S2666-5247(24)00149-6
• Stoycheva K, et al. Tuberculosis in people of Ukrainian origin in the European Union and the European Economic Area, 2019 to 2022. Stoycheva K, Cristea V, Ködmön C, Rosales-Klintz S, Zenner D, Vasiliu A, van der Werf M, Lange C. Euro Surveill. 2024 Mar;29(12). doi: 10.2807/1560-7917.ES.2024.29.12.2400094.
• Wetzstein N, et al. Clinical spectrum and relevance of Mycobacterium malmoense: systematic review and meta-analysis of 859 patients. J Infect. 2024 Jun 19:106203. doi: 10.1016/j.jinf.2024.106203.
• Zielinski N, et al. A transcriptomic biomarker predicting linezolid-associated neuropathy during treatment of drug-resistant tuberculosis. Pathog Immun 2024 25;9(2):25-42. doi: 10.20411/pai.v9i2.705. eCollection 2024.

2023

• Chesov E, et al. Impact of Mycobacterium tuberculosis strain type on multidrug-resistant tuberculosis severity, Republic of Moldova. J Infect. 2023 Oct 10:S0163-4453(23)00532-7. doi: 10.1016/j.jinf.2023.10.001.
• COVID-19 Host Genetics Initiative. A second update on mapping the human genetic architecture of COVID-19. Nature 2023
• Dominguez J, et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infect Dis. 2023 Feb 28:S1473-3099(22)00875-1. doi: 10.1016/S1473-3099(22)00875-1.
• Hamada Y, et al. Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis. EClinicalMedicine. 2023 Jan 5;56:101815. doi: 10.1016/j.eclinm.2022.101815.
• Koehler N, et al. Pretomanid-resistant tuberculosis. J Infect. 2023 Feb 2:S0163-4453(23)00069-5. doi: 10.1016/j.jinf.2023.01.039.
• Lange C, et al. Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2023 Jan 12;388(2):190. doi: 10.1056/NEJMc2213970.
• Lange C, et al. Emerging bedaquiline-resistant tuberculosis. Lancet Microbe 2023 November 3, 2023 https://doi.org/10.1016/S2666-5247(23)00321-X
• Lange C. Mission (im)possible: elimination of tuberculosis. Clin Microbiol Infect. 2023 Aug 4:S1198-743X(23)00361-0. doi: 10.1016/j.cmi.2023.07.033.
• Maier C, et al. Long-term treatment outcomes in multidrug-resistant tuberculosis Clin Microbiol Infect. 2023 Feb 24:S1198-743X(23)00083-6. doi: 10.1016/j.cmi.2023.02.013.
• Motta I, et al. Recent advances in the treatment of tuberculosis. Clin Microbiol Infect. 2023 Jul 21:S1198-743X(23)00339-7. doi: 10.1016/j.cmi.2023.07.013.
• Noroc E, et al. Limited nosocomial transmission of drug-resistant-tuberculosis, R. Moldova. Emerg Infect Dis 2023 May;29(5):1046-1050. doi: 10.3201/eid2905.230035.
• Pedersen OS, et al. Global treatment outcomes of extensively drug-resistant tuberculosis in adults: A systematic review and meta-analysis. J Infect 2023 Jun 23:S0163-4453(23)00337-7. doi: 10.1016/j.jinf.2023.06.014.
• Salzer HJF, et al. Aspergillus-specific IgG antibodies for diagnosing chronic pulmonary aspergillosis compared to the reference gold standard. Clin Microbiol Infect. 2023 Sep 7:S1198-743X(23)00416-0. doi: 10.1016/j.cmi.2023.08.032.
• Vasiliu A*, et al. Tuberculosis in foreign-born persons in Europe. Euro Surveill. 2023 Oct;28(42):2300051. doi: 10.2807/1560-7917.ES.2023.28.42.2300051.

2022

• Bergeron A et al.  European Conference on Infections in Leukaemia group. Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia. Lancet Infect Dis. 2022 May 27:S1473-3099(22)00227-4. doi: 10.1016/S1473-3099(22)00227-4.
• Chesov E, et al. Emergence of bedaquiline resistance in a high tuberculosis burden country. Eur Respir J. 2022 Mar 24;59(3):2100621. doi: 10.1183/13993003.00621-2021.
• Dheda K, et al. A revolution in the management of multidrug-resistant tuberculosis. Lancet. 2022 Nov 26;400(10366):1823-1825. doi: 10.1016/S0140-6736(22)02161-4. 18
• DiNardo AR, et al. Gene expression signatures identify biologically and clinically distinct tuberculosis endotypes. Eur Respir J. 2022 Feb 15:2102263. doi: 10.1183/13993003.02263-2021.
• Günther G, et al. Availability and costs of medicines for the treatment of tuberculosis in Europe. Clin Microbiol Infect. 2022 Aug 10:S1198-743X(22)00394-9. doi: 10.1016/j.cmi.2022.07.026.
• Guglielmetti L, et al. Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and; Tuberculosis Network European Trials group (TBnet). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. Eur Respir J. 2022 May 19;59(5):2200388. doi: 10.1183/13993003.00388-2022.
• Lange C, et al. on behalf of the expert panel group for management recommendations in NTM-PD. Consensus management recommendations for additional nontuberculous mycobacterial pulmonary diseases. Lancet Infect Dis. 2022 Jan 25:S1473-3099(21)00586-7. doi: 10.1016/S1473-3099(21)00586-7.
• Lange C, et al. Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel. Am J Respir Crit Care Med. 2022 Mar 23. doi: 10.1164/rccm.202202-0393ED.
• Martinez L, et al. Childhood BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: An individual-participant meta-analysis of 26 Cohort Studies. Lancet Global Health 2022 Sep;10(9):e1307-e1316. doi: 10.1016/S2214-109X(22)00283-2.
• Otto-Knapp R, et al. Long-term MDR/RR-TB treatment outcome by new WHO definitions in Germany. Eur Respir J. 2022 Nov 24;60(5):2200765. doi: 10.1183/13993003.00765-2022.
• Sibandze D, et al. Rapid molecular diagnostics of tuberculosis resistance by targeted stool sequencing. Genome Med. 2022 May 19;14(1):52. doi: 10.1186/s13073-022-01054-6.
• Tunesi S, et al. Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study. J Infect. 2022 Jun;84(6):834-872. doi: 10.1016/j.jinf.2022.03.004.
• v Braeckel E, et al. for CPAnet. Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement. Eur Respir J. 2022 Jun 9;59(6):2102950. doi: 10.1183/13993003.02950-2021.

Download CV Christoph Lange (PDF)